newsfilter
← Latest News
PR Newswire·

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

TYRA
  • Tyra Biosciences appointed Bhavesh Ashar as Chief Operating Officer, effective immediately, and Heather Faulds as Chief Regulatory Officer, effective December 8, 2025.
  • Ashar & Faulds will lead the advancement of oral dabogratinib through global Phase 2 studies in skeletal dysplasia & urologic cancers while preparing for potential Phase 3 trials.
  • Bhavesh Ashar brings over 25 years of experience, most recently serving as Chief Commercial Officer at SpringWorks Therapeutics until its 2025 acquisition by Merck KGaA.
  • Heather Faulds brings over 20 years of regulatory experience, including leading approvals for SPINRAZA & LYBALVI during her tenure at Blueprint Medicines, Fulcrum Therapeutics, Alkermes, Scholar Rock, & Biogen.
  • Oral dabogratinib is an investigational FGFR3-selective inhibitor developed via Tyra's SNÅP platform, currently in Phase 2 trials for pediatric achondroplasia, non-muscle invasive bladder cancer, & upper tract urothelial carcinoma.
  • The FDA has granted Orphan Drug Designation & Rare Pediatric Disease Designation to dabogratinib for the treatment of achondroplasia.
  • Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, focused on precision medicines targeting FGFR biology.